Outcomes of ultra‐low contrast percutaneous coronary intervention in patients with advanced chronic kidney disease

Abstract

AbstractBackgroundCoronary angiography and percutaneous coronary intervention (PCI) in patients with chronic kidney disease (CKD) is associated with increased risk of contrast induced nephropathy (CIN) and requirement for renal replacement therapy (RRT).ObjectivesWe aimed to evaluate our single center experience of ultra‐low contrast PCI in patients with CKD and to characterize 1 year outcomes.MethodsWe performed a retrospective analysis of ultra‐low contrast PCI at our institution between 2016 and 2022. Patients with CKD3b‐5 (eGFR <45 mL/min/1.73m2), not on RRT who underwent ultra‐low contrast PCI ( < 30 mL of contrast during PCI) were included. Primary outcomes included change in eGFR post‐procedurally, and death, RRT requirement, and major adverse cardiac events (MACE) at 1 year follow‐up.ResultsOne hundred patients were included in the study. The median age was 67 years old and 28% were female. The median baseline eGFR was 21.5 mL/min/1.73m2 (IQR 14.08–32.0 mL/min/1.73m2). A median of 8.0 mL (IQR 0–15 mL) of contrast was used during PCI. Median contrast use to eGFR ratio was 0.37 (IQR 0‐0.59). There was no significant difference between pre‐and postprocedure eGFR (p = 0.84). At 1 year, 8% of patients died, 11% required RRT and 33% experienced MACE. The average time of RRT initiation was 7 months post‐PCI. Forty‐four patients were undergoing renal transplant evaluation, of which 17 (39%) received a transplant.ConclusionsIn patients with advanced CKD, ultra‐low contrast PCI is feasible and safe with minimal need for peri‐procedural RRT. Moreover, ultra‐low contrast PCI may allow for preservation of renal function in anticipation of renal transplantation.